Compare LARK & KRRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LARK | KRRO |
|---|---|---|
| Founded | 1885 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 171.0M | 150.0M |
| IPO Year | 2001 | 2019 |
| Metric | LARK | KRRO |
|---|---|---|
| Price | $27.58 | $10.39 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $34.80 |
| AVG Volume (30 Days) | 3.5K | ★ 72.9K |
| Earning Date | 04-29-2026 | 05-13-2026 |
| Dividend Yield | ★ 3.07% | N/A |
| EPS Growth | ★ 35.84 | N/A |
| EPS | ★ 0.83 | N/A |
| Revenue | N/A | ★ $6,392,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $33.46 | ★ N/A |
| Revenue Growth | N/A | ★ 181.46 |
| 52 Week Low | $23.43 | $5.20 |
| 52 Week High | $30.80 | $55.89 |
| Indicator | LARK | KRRO |
|---|---|---|
| Relative Strength Index (RSI) | 51.32 | 32.63 |
| Support Level | $27.01 | $9.90 |
| Resistance Level | $28.76 | $14.52 |
| Average True Range (ATR) | 0.85 | 0.83 |
| MACD | -0.02 | -0.33 |
| Stochastic Oscillator | 57.50 | 2.08 |
Landmark Bancorp Inc is the bank holding company for Landmark National Bank, which is dedicated to providing quality financial and banking services. The Bank has continued to focus on increasing its originations of commercial, commercial real estate (CRE), and agricultural loans, which management believes will be more profitable and provide more growth for the Bank than traditional one-to-four-family residential real estate lending. In addition, it also invests in certain investment and mortgage-related securities using deposits and other borrowings as funding sources. Its primary deposit gathering and lending markets are geographically diversified with locations in central, eastern, southeast, and Southwest Kansas.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. The company operates and manages its business as one reportable segment and one operating segment, which is the business of discovering, developing and commercializing therapies derived from or incorporating its RNA-editing technology.